Clinical Application of Automatic Gene Chip Analyzer (WEnCA-Chipball) for Mutant Kras Detection in Peripheral Circulating Cancer Cells of Cancer Patients

Hsiung, Suz-Kai; Lin, Shiu‐Ru; Chang, Hao‐Ming; Chen, Yifang

doi:10.5772/12940

Cited by 3 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the specificity (92.0%) and accuracy (91.3%), but not the sensitivity (87.5%), of the biomarker chip were similar to those reported in previous studies that used the WEnCA platform [18][19][20][21][22]. The false-positive rate of the biomarker chip in early prediction of postoperative relapse was 32.3%; nevertheless, postoperative serum CEA levels showed a higher false-positive rate (59.2%).…”

Section: Discussionsupporting

confidence: 69%

“…Of the two independent predictors of relapse, our multigene biomarker biochip was more accurate than postoperative serum CEA levels (91.3% vs. 79.5%, P < 0.001). Moreover, the median lead time between positive biochip results and relapse detection was 10.7 months, considerably earlier than that between elevated postoperative serum CEA levels and relapse detection (2.8 months, [18,21,22]. The selection of the target gene and modification of the weighted values for the corresponding genes contribute the most to the accuracy in clinical applications.…”

Section: Discussionmentioning

confidence: 99%

“…Each overexpressed spot was then multiplied by the respective weighted values ranging from 1 to 4, according to the principle described previously [18][19][20][21][22].…”

Section: Biomarker Chip Interventionmentioning

confidence: 99%

See 2 more Smart Citations

A prospective study comparing multi-gene biomarker chip and serum carcinoembryonic antigen in the postoperative surveillance for patients with stage I–III colorectal cancer

Wang¹

2016

European Journal of Cancer

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A prospective study comparing multi-gene biomarker chip and serum carcinoembryonic antigen in the postoperative surveillance for patients with stage I–III colorectal cancer

Wang¹

2016

European Journal of Cancer

View full text Add to dashboard Cite

“…A weighted enzymatic chip array (WEnCA) platform is a sensitive technique for detecting activated KRAS from the peripheral blood in patients with various malignancies [ 18 , 21 , 22 ]. The selection of the target gene and modification of the weighted values for the corresponding genes contribute the most to the accuracy in clinical applications.…”

Section: Discussionmentioning

confidence: 99%

“…If the gene presented a color density >2-fold higher than the positive control (β-actin) did, the result was defined as positive, whereas if the density was <2-fold higher than that of the positive control, the result was defined as negative. Each overexpressed spot was then multiplied by the respective weighted values ranging from 1 to 4, according to the principle described previously [ 18 – 22 ].…”

Section: Methodsmentioning

confidence: 99%

A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer

Chang¹,

Yeh²,

Huang³

et al. 2016

PLoS ONE

Self Cite

View full text Add to dashboard Cite

BackgroundCirculating biomarkers can predict clinical outcomes in colorectal cancer patients. The aim of the study was to evaluate the feasibility of our multigene biomarker chip for detecting circulating tumor cells for postoperative surveillance of stage I–III colorectal cancer patients.Materials and MethodsIn total, 298 stage I–III colorectal cancer patients were analyzed after curative resection between June 2010 and October 2014. During each follow-up, a postoperative surveillance strategy, including ESMO Guidelines Working Group recommendations and the biochip, was used.ResultsAfter a 28.4-month median follow-up, 48 (16.1%) patients had postoperative relapse. Univariate analysis revealed that the postoperative relapse risk factors were rectal tumor, perineural invasion, elevated preoperative and postoperative serum carcinoembryonic antigen levels, and positive biochip results (all P < 0.05). Multivariate analyses revealed that postoperative relapse correlated significantly with elevated postoperative serum carcinoembryonic antigen levels (odds ratio = 4.136, P = 0.008) and positive biochip results (odds ratio = 66.878, P < 0.001). However, the sensitivity (P = 0.003), specificity (P = 0.003), positive (P = 0.002) and negative (P = 0.006) predictive values, and accuracy (P < 0.001) of the biochip for predicting postoperative relapse were significantly higher than those of elevated postoperative serum carcinoembryonic antigen levels. Moreover, the median lead time between positive biochip result and postoperative relapse detection was significantly earlier than that between elevated postoperative serum carcinoembryonic antigen level and postoperative relapse detection (10.7 vs. 2.8 months, P < 0.001). Furthermore, positive biochip results correlated strongly with lower disease-free survival and overall survival of colorectal cancer patients (both P < 0.001).ConclusionCompared with conventional serum carcinoembryonic antigen detection, our multigene chip aided more accurate and earlier prediction of postoperative relapse during stage I–III colorectal cancer patient surveillance. In clinical practice, this biochip may facilitate early postoperative relapse diagnosis in colorectal cancer patients.

show abstract

Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundThe KRAS oncogene was one of the earliest discoveries of genetic alterations in colorectal and lung cancers. Moreover, KRAS somatic mutations might be used for predicting the efficiency of anti-EGFR therapeutic drugs. The purpose of this research was to improve Activating KRAS Detection Chip by using a weighted enzymatic chip array (WEnCA) platform to detect activated KRAS mutations status in the peripheral blood of non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC) patients in Taiwan.MethodsOur laboratory developed an Activating KRAS Detection Chip and a WEnCA technique that can detect activated KRAS mutation status by screening circulating cancer cells in the surrounding bloodstream. We collected 390 peripheral blood samples of NSCLC patients (n = 210) and CRC patients (n = 180) to evaluate clinical KRAS activation using this gene array diagnosis apparatus, an Activating KRAS Detection Chip and a WEnCA technique. Subsequently, we prospectively enrolled 88 stage III CRC patients who received adjuvant FOLFOX-4 chemotherapy with or without cetuximab. We compared the chip results of preoperative blood specimens and their relationship with disease control status in these patients.ResultsAfter statistical analysis, the sensitivity of WEnCA was found to be 93%, and the specificity was found to be 94%. Relapse status and chip results among the stage III CRC patients receiving FOLFOX-4 plus cetuximab (n = 59) and those receiving FOLFOX-4 alone (n = 29) were compared. Among the 51 stage III CRC patients with chip negative results who were treated with FOLFOX-4 plus cetuximab chemotherapy, the relapse rate was 33.3%; otherwise, the relapse rate was 48.5% among the 23 out of 88 patients with chip negative results who received FOLFOX-4 alone. Negative chip results were significantly associated to better treatment outcomes in the FOLFOX-4 plus cetuximab group (P = 0.047).ConclusionsThe results demonstrated that the WEnCA technique is a sensitive and convenient technique that produces easy-to-interpret results for detecting activated KRAS from the peripheral blood of cancer patients. We suggest that the WEnCA technique is also a potential tool for predicting responses in CRC patients following FOLFOX-4 plus cetuximab chemotherapy.

show abstract

Clinical Application of Automatic Gene Chip Analyzer (WEnCA-Chipball) for Mutant Kras Detection in Peripheral Circulating Cancer Cells of Cancer Patients

Cited by 3 publications

References 38 publications

A prospective study comparing multi-gene biomarker chip and serum carcinoembryonic antigen in the postoperative surveillance for patients with stage I–III colorectal cancer

A prospective study comparing multi-gene biomarker chip and serum carcinoembryonic antigen in the postoperative surveillance for patients with stage I–III colorectal cancer

A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer

Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array

Contact Info

Product

Resources

About